References
- Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isoenzyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429–5433.
- Groenen PMA, Bunschoten AE, Soolingen DV, et al. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol. 1993;10(5):1057–1065.
- Mojica FJM, Rodriguez-Valera F. The discovery of CRISPR in archaea and bacteria. FEBS J. 2016;283(17):3162–3169.
- Jansen R, van Embden JDA, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43(6):1565–1575.
- Bolotin A, Quinquis B, Sorokin A, et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiol (N Y). 2005;151:2551–2561.
- Makarova KS, Grishin NV, Shabalina SA, et al. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct. 2006;1(1):1–26.
- Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–1712. 1979.
- BrounsRutering J, Ilmer M, Recio A, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;5:1–8. 1979.
- Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. 2008;322(5909):1843–1845. 1979.
- Garneau JE, Dupuis MÈ, Villion M, et al. The CRISPR/cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468(7320):67–71.
- Gasiunas G, Barrangou R, Horvath P, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012;109(39):2579–2586.
- Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471(7340):602–607.
- Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826. 1979.
- Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–823. 1979.
- Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein and Cell. 2015;6(5):363–372.
- Charpentier E. The nobel prize in chemistry 2020 popular science background genetic scissors: a tool for rewriting the code of life. 2020.
- Nidhi S, Anand U, Oleksak P, et al. Novel CRISPR–cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci. 2021;22(7):3327. https://pmc/articles/PMC8036902/
- Wang X, Dong K, Kong D, et al. A far-red light–inducible CRISPR-Cas12a platform for remote-controlled genome editing and gene activation. Sci Adv. 2021:7(50). DOI:10.1126/sciadv.abh2358.
- Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides against viruses in prokaryotes. Science. 2007;315(5819):1709–1712. 1979.
- Wan F, Draz MS, Gu M, et al. Novel Strategy to combat antibiotic resistance: a sight into the combination of CRISPR/Cas9 and nanoparticles. Pharmaceutics. 2021;13(3):352. https://www.mdpi.com/1999-4923/13/3/352/htm
- Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided Dual-RNA–Guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821. 1979.
- Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system. Methods Mol Biol. 2015;1239:197–217.
- Nakamura M, Okamura Y, Iwai H. Plasmid-based and -free methods using CRISPR/Cas9 system for replacement of targeted genes in colletotrichum sansevieriae.Sci Rep. 2019;9(1):1–10.
- Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science 1979). 2014;346. (6213): https://www.science.org/doi/abs/10.1126/science.1258096
- van Pijkeren JP, Britton RA. Precision genome engineering in lactic acid bacteria. Microb Cell Fact. 2014;13(Suppl 1):1–10.
- Stovicek V, Holkenbrink C, Borodina I. CRISPR/Cas system for yeast genome engineering: advances and applications. FEMS Yeast Res. 2017;17(5):1–16.
- Soppe JA, Lebbink RJ. Antiviral goes viral: harnessing CRISPR/cas9 to combat viruses in humans. Trends Microbiol. 2017;25(10):833–850.
- Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624–641.
- Zhang WW, Karmakar S, Gannavaram S, et al. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat Commun. 2020;11(1):1–14.
- Gill SS, Gill R, Tuteja R, et al. Genetic engineering of crops: a ray of hope for enhanced food security. Plant Signal Behav. 2014;9(3):7–10.
- Shen B, Zhang W, Zhang J, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399–402.
- Edvardsen RB, Leininger S, Kleppe L, et al. Targeted mutagenesis in Atlantic salmon (Salmo salar L.) using the CRISPR/Cas9 system induces complete knockout individuals in the F0 generation. PLoS ONE. 2014;9(9):e108622.
- Petazzi P, Menéndez P, Sevilla A. CRISPR/Cas9–mediated gene knockout and knockin human iPSCs.Methods Mol Biol. 2020;36:2093–2103.
- Wu SS, Li QC, Yin CQ, et al. Advances in CRISPR/cas-based gene therapy in human genetic diseases. Theranostics. 2020;10(10):4374–4382.
- Hübner A, Petersen B, Keil GM, et al. Efficient inhibition of African swine fever virus replication by CRISPR/Cas9 targeting of the viral p30 gene (CP204L). Sci Rep. 2018;8(1):8.
- V BM, O’Donnell V, Holinka LG, et al. Deletion of CD2-like gene from the genome of African swine fever virus strain Georgia does not attenuate virulence in swine. Sci Rep. 2020;10(1):10.
- V BM, Holinka LG, Berggren KA, et al. CRISPR-Cas9, a tool to efficiently increase the development of recombinant African swine fever viruses. Sci Rep. 2018;8(1):8.
- Abkallo HM, Svitek N, Oduor B, et al. Rapid CRISPR/Cas9 editing of genotype IX African swine fever virus circulating in Eastern and Central Africa. Front Genet. 2021;30(12):733674 DOI: 10.3389/fgene.2021.733674.
- Daniloski Z, Jordan TX, Wessels HH, et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell. 2021;184(1):92–105.e16. http://www.cell.com/article/S0092867420313945/fulltext
- Wei J, Alfajaro MM, DeWeirdt PC, et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell. 2021;184(1):76–91.e13 [Cited 18 April 2022]. http://www.cell.com/article/S0092867420313921/fulltext
- Li H, Wang S, Dong X, et al. CRISPR-Cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication. Mol Ther Nucleic Acids. 2020;19:1460–1469.
- Zheng Q, Bai L, Zheng S, et al. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system. Mol Med Rep. 2017;16(5):7199–7204.
- Wang B, Wang Y, Frabutt DA, et al. Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J Biol Chem. 2017;292(14):5860–5870.
- Al MHMA, Watanabe T, Yoshida M, et al. Epstein-barr virus BKRF4 gene product is required for efficient progeny production. J Virol. 2017;91(23):e00975–17.
- Al Masud HMA, Yanagi Y, Watanabe T, et al. Epstein-barr virus BBRF2 is required for maximum infectivity. Microorganisms. 2019;7(12):705.
- Al MHMA, Watanabe T, Sato Y, et al. The BOLF1 gene is necessary for effective Epstein–Barr viral infectivity. Virology. 2019;531:114–125.
- Wang J, Quake SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A. 2014;111(36):13157–13162.
- Yuen KS, Wang ZM, Wong NHM, et al. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. Virus Res. 2018;244:296–303.
- van Diemen FR, Kruse EM, Hooykaas MJG, et al. CRISPR/cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog. 2016;12(6):e1005701.
- Murphy BG, Wolf T, Vogel H, et al. An RNA-directed gene editing strategy for attenuating the infectious potential of feline immunodeficiency virus-infected cells: a proof of concept. Viruses. 2020;12(5):511.
- Bierle CJ, Anderholm KM, Ben WJ, et al. Targeted mutagenesis of guinea pig cytomegalovirus using CRISPR/Cas9-mediated gene editing. J Virol. 2016;90(15):6989–6998 [cited 18 April 2022]. https://journals.asm.org/doi/abs/10.1128/JVI.00139-16
- Jiang X, Kanda T, Haga Y, et al. Glucose-regulated protein 78 is an antiviral against hepatitis a virus replication. Exp Ther Med. 2017;13(6):3305–3308. http://www.spandidos-publications.com/10.3892/etm.2017.4407/abstract
- Li H, Sheng C, Wang S, et al. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91.
- Wang J, Xu ZW, Liu S, et al. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol. 2015;21(32):9554–9565.
- Xu Y, Qi Y, Luo J, et al. Hepatitis B virus X protein stimulates proliferation, wound closure and inhibits apoptosis of HuH-7 cells via CDC42. Int J Mol Sci. 2017;18(3):586.
- Liu Y, Qi X, Zeng Z, et al. CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Sci Rep. 2017;7:2796.
- Zhu W, Xie K, Xu Y, et al. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res. 2016;217:125–132.
- Karimova M, Beschorner N, Dammermann W, et al. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep. 2015;5(1). DOI:10.1038/srep13734.
- Zhou SJ, Deng YL, Liang HF, et al. Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and notch signaling in hepatocellular carcinoma. Cell Death Differ. 2017;24(9):1577–1587.
- Qi Y, Gao Z, Xu G, et al. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog. 2016;12(10):e1005893.
- Ren Q, Li C, Yuan P, et al. A Dual-Reporter system for real-time monitoring and high-throughput CRISPR/cas9 library screening of the hepatitis C virus. Sci Rep. 2015;5(1). DOI:10.1038/srep08865.
- Yamauchi S, Takeuchi K, Chihara K, et al. STAT1 is essential for the inhibition of hepatitis C virus replication by interferon-λ but not by interferon-α. Sci Rep. 2016;6(1):6.
- Domingues P, Bamford CGG, Boutell C, et al. Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase. J Gen Virol. 2015;96(11):3236–3242.
- Xu X, Fan S, Zhou J, et al. The mutated tegument protein UL7 attenuates the virulence of herpes simplex virus 1 by reducing the modulation of α-4 gene transcription. Virol J. 2016;13(1). DOI:10.1186/s12985-016-0600-9.
- Fan S, Xu X, Liao Y, et al. Attenuated phenotype and immunogenic characteristics of a mutated herpes simplex virus 1 strain in the rhesus macaque. Viruses. 2018;10(5):234.
- Ebrahimi S, Makvandi M, Abbasi S, et al. Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9. Iran J Basic Med Sci. 2020;23(7):937–944.
- Khodadad N, Fani M, Jamehdor S, et al. A knockdown of the herpes simplex virus type-1 gene in all-in-one CRISPR vectors. Folia Histochem Cytobiol. 2020;58(3):174–181.
- Oh HS, Neuhausser WM, Eggan P, et al. Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9. Elife. 2019;8:e51662.
- Chen Y, Zhi S, Liang P, et al. Single AAV-mediated CRISPR-SaCas9 inhibits HSV-1 replication by editing ICP4 in trigeminal ganglion neurons. Mol Therapy - Methods Clin Develop. 2020;18:33–43.
- Suenaga T, Kohyama M, Hirayasu K, et al. Engineering large viral DNA genomes using the CRISPR-Cas9 system. Microbiol Immunol. 2014;58(9):513–522.
- Liu L, Cheng J, Mou T, et al. The mutation of the genes related to neurovirulence in HSV-2 produces an attenuated phenotype in mice. Viruses. 2020;12(7):770.
- Cai L, Hu H, Duan H, et al. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology. J Med Virol. 2020;92(12):3617–3627.
- Gao J, Yan X, Banfield BW. Comparative analysis of UL16 mutants derived from multiple strains of herpes simplex virus 2 (HSV-2) and HSV-1 reveals species-specific requirements for the UL16 protein. J Virol. 2018;92(13). DOI:10.1128/JVI.00629-18
- Finnen RL, Banfield BW. CRISPR/Cas9 mutagenesis of UL21 in multiple strains of herpes simplex virus reveals differential requirements for pUL21 in viral replication. Viruses. 2018;10(5):258.
- Ibba G, Piu C, Uleri E, et al. Disruption by SaCas9 endonuclease of HERV-Kenv, a retroviral gene with oncogenic and neuropathogenic potential, inhibits molecules involved in cancer and amyotrophic lateral sclerosis. Viruses. 2018;10(8):412.
- Bulli L, Apolonia L, Kutzner J, et al. Complex interplay between HIV-1 Capsid and MX2-Independent alpha interferon-induced antiviral factors. J Virol. 2016;90(16):7469–7480.
- Zhou T, Frabutt DA, Moremen KW, et al. ERManI (Endoplasmic reticulum class Iα-mannosidase) is required for HIV-1 envelope glycoprotein degradation via endoplasmic reticulum-associated protein degradation pathway. J Biol Chem. 2015;290(36):22184–22192.
- Kaminski R, Bella R, Yin C, et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 2016;23(8–9):690–695.
- Zhou T, Dang Y, Zheng Y-H. The mitochondrial translocator protein, TSPO, Inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway. J Virol. 2014;88(6):3474–3484.
- Bonifati S, Daly MB, St.gelais C, et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology. 2016;495:92–100.
- Meng B, NCY I, Prestwood LJ, et al. Evidence that the endosomal sorting complex required for transport-II (ESCRT-II) is required for efficient human immunodeficiency virus-1 (HIV-1) production. Retrovirology. 2015;12:12.
- Kaminski R, Chen Y, Fischer T, et al. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep. 2016;6(1):6.
- Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014;111(31):11461–11466.
- Hou P, Chen S, Wang S, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015;5(1). DOI:10.1038/srep15577.
- Dufrasne FE, Lombard C, Goubau P, et al. Single amino acid substitution N659D in HIV-2 envelope glycoprotein (Env) impairs viral release and hampers BST-2 antagonism. Viruses. 2016;8(10):285[cited 18 April 2022].https://www.mdpi.com/1999-4915/8/10/285/htm.
- Li C, Guo L, Liu G, et al. Reprogrammed CRISPR-Cas13a targeting the HPV16/18 E6 gene inhibits proliferation and induces apoptosis in E6-transformed keratinocytes. Exp Ther Med. 2020;19(6):3856–3860.
- Bortnik V, Wu M, Julcher B, et al. Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells. J Microbiol Immunol Infect. 2021;54(4):733–739.
- Tso FY, West JT, Wood C. Reduction of Kaposi’s sarcoma-associated herpesvirus latency using CRISPR-cas9 to edit the latency-associated nuclear antigen gene. J Virol. 2019;93.
- Xiao B, Yin S, Hu Y, et al. Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2019;116(1):255–260. https://pubmed.ncbi.nlm.nih.gov/30584102/
- Wollebo HS, Bellizzi A, Kaminski R, et al. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection. PLOS ONE. 2015;10(9):e0136046. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136046
- Chou YY, Krupp A, Kaynor C, et al. Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep. 2016;6(1):6.
- Ren J, Wang H, Zhou L, et al. Glycoproteins C and D of PRV strain HB1201 contribute individually to the escape from Bartha-K61 vaccine-induced immunity. Front Microbiol. 2020;11:323.
- Ye C, Chen J, Wang T, et al. Generation and characterization of UL41 null pseudorabies virus variant in vitro and in vivo. Virol J. 2018;15(1):15.
- Yin H, Li Z, Zhang J, et al. Construction of a US7/US8/UL23/US3-deleted recombinant pseudorabies virus and evaluation of its pathogenicity in dogs. Vet Microbiol. 2020;240:108543.
- Yuan M, Gao X, Chard LS, et al. A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. Mol Therapy - Methods Clin Develop. 2015;2:15035.
- Purusothaman DK, Shackleford L, Anderson MAE, et al. CRISPR/Cas-9 mediated knock-in by homology dependent repair in the West Nile virus vector culex quinquefasciatus say. Sci Rep. 2021;11(1):1–8. https://www.nature.com/articles/s41598-021-94065-z
- Huang Y, Lin Q, Huo Z, et al. Inositol-requiring enzyme 1α promotes zika virus infection through regulation of stearoyl coenzyme a desaturase 1-mediated lipid metabolism. J Virol. 2020;94(23). DOI:10.1128/JVI.01229-20.
- Darcis G, Kuriakose T, Jongkaewwattana A, et al. Application of CRISPR/Cas9 in understanding avian viruses and developing poultry vaccines. Front Cell Infect Microbiol. 2020;1:581504 doi:https://doi.org/10.3389/fcimb.2020.581504.
- Peng Q, Fang L, Ding Z, et al. Rapid manipulation of the porcine epidemic diarrhea virus genome by CRISPR/Cas9 technology. J Virol Methods. 2020;276:113772.
- Wang G, Liang R, Liu Z, et al. The N-Terminal domain of spike protein is not the enteric tropism determinant for transmissible gastroenteritis virus in piglets. Viruses. 2019;11. https://pubmed.ncbi.nlm.nih.gov/30935078/
- Zhang Y, Tang N, Sadigh Y, et al. Application of CRISPR/Cas9 gene editing system on MDV-1 Z. Viruses. 2018;10(6):279. https://www.mdpi.com/1999-4915/10/6/279/htm
- Yin H, Li Z, Zhang J, et al. Construction of a US7/US8/UL23/US3-deleted recombinant pseudorabies virus and evaluation of its pathogenicity in dogs. Vet Microbiol. 2020;240:108543. https://pubmed.ncbi.nlm.nih.gov/31902487/
- Teng M, Yao Y, Nair V, et al. Latest advances of virology research using CRISPR/Cas9-based gene-editing technology and its application to vaccine development. Viruses. 2021;13(5):779. https://www.mdpi.com/1999-4915/13/5/779/htm
- Vergara-Mendoza M, Gomez-Quiroz LE, Miranda-Labra RU, et al. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation. Antiviral Res. 2020;180:104856.
- Hagag IT, Wight DJ, Bartsch D, et al. Abrogation of Marek’s disease virus replication using CRISPR/Cas9. Sci Rep. 2020;10(1):10.
- Gao Z, Fan M, Das AT, et al. Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Res. 2020;48(10):5527. /pmc/articles/PMC7261156/
- Yin L, Zhao F, Sun H, et al. CRISPR-Cas13a inhibits HIV-1 infection. Mol Ther Nucleic Acids. 2020;21:147–155.
- Zheng K, Jiang FF, Su L, et al. Highly Efficient base editing in viral genome based on bacterial artificial chromosome using a cas9-cytidine deaminase fused protein. Virol Sin. 2020;35(2):191–199. https://link.springer.com/article/10.1007/s12250-019-00175-4
- Woźniakowski G, Mazur-Panasiuk N, Walczak M, et al. Attempts at the development of a recombinant African swine fever virus strain with abrogated EP402R, 9GL, and A238L gene structure using the CRISPR/Cas9 system. J Veterinary Res (Poland). 2020;64(2):197–205.
- Zhang Y, Tang N, Luo J, et al. Marek’s Disease virus-encoded MicroRNA 155 ortholog critical for the induction of lymphomas is not essential for the proliferation of transformed cell lines. J Virol. 2019:93(17). DOI:10.1128/JVI.00713-19.
- BeltCappellino A, Majerciak V, Lobanov A, et al. CRISPR/Cas9-mediated knockout and in situ inversion of the ORF57 gene from all copies of the kaposi’s sarcoma-associated herpesvirus genome in BCBL-1 cells. J Virol. 2019;93(21):e00628–19.
- Gabaev I, Williamson JC, Crozier TWM, et al. Quantitative proteomics analysis of lytic KSHV infection in human endothelial cells reveals targets of viral immune modulation. Cell Rep. 2020;33(2):108249. https://europepmc.org/articles/PMC7567700
- Peng Z, Ouyang T, Pang D, et al. Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition. Virus Res. 2016;223:197–205.
- Lin C, Li H, Hao M, et al. Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci Rep. 2016;6(1):1–13. https://www.nature.com/articles/srep34531
- Yuan M, Zhang W, Wang J, et al. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J Virol. 2015;89(9):5176–5179. https://pubmed.ncbi.nlm.nih.gov/25741005/
- Ling X, Xie B, Gao X, et al. Improving the efficiency of precise genome editing with site-specific Cas9-oligonucleotide conjugates. Sci Adv. 2020;6(15):eaaz0051.
- Gong Y, Bi Y, Li Z, et al. High-efficiency nonhomologous insertion of a foreign gene into the herpes simplex virus genome. J Gen Virol. 2020;101(9):982–996.
- Tang N, Zhang Y, Pedrera M, et al. A simple and rapid approach to develop recombinant avian herpesvirus vectored vaccines using CRISPR/Cas9 system. Vaccine. 2018;36(5):716–722.
- Tang YD, Liu JT, Wang TY, et al. Comparison of pathogenicity-related genes in the current pseudorabies virus outbreak in China. Sci Rep.2017;7(1):7783.
- Zhang L, Huang R, Lu L, et al. Gene knock-in by CRISPR/Cas9 and cell sorting in macrophage and T cell lines. J Vis Exp. 202:e62328 doi:https://doi.org/10.3791/62328.
- Qing YZ, Tong W, Zheng H, et al. Variations in glycoprotein B contribute to immunogenic difference between PRV variant JS-2012 and Bartha-K61. Vet Microbiol. 2017;208:97–105.
- Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183.
- Limsirichai P, Gaj T, V SD. CRISPR-mediated activation of latent HIV-1 expression. Mol Ther. 2016;24(3):499–507.
- Villamizar O, Waters SA, Scott T, et al. Targeted activation of cystic fibrosis transmembrane conductance regulator. Mol Ther. 2019;27(10):1737–1748. http://www.cell.com/article/S1525001619303144/fulltext
- Olson A, Basukala B, Lee S, et al. Targeted chromatinization and repression of HIV-1 provirus transcription with repurposed CRISPR/Cas9. Viruses. 2020;12(10):1154. https://www.mdpi.com/1999-4915/12/10/1154/htm
- Price AA, Sampson TR, Ratner HK, et al. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A. 2015;112(19):6164–6169. https://europepmc.org/articles/PMC4434742
- Freije CA, Myhrvold C, Boehm CK, et al. Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell. 2019;76(5):826–837.e11. https://pubmed.ncbi.nlm.nih.gov/31607545/
- Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and Influenza. Cell. 2020;181(4):865. /pmc/articles/PMC7189862/
- Papa G, Venditti L, Braga L, et al. CRISPR-Csy4-mediated editing of rotavirus double-stranded RNA genome. Cell Rep. 2020;32(13):108205. http://www.cell.com/article/S2211124720311943/fulltext
- Strutt SC, Torrez RM, Kaya E, et al. RNA-dependent RNA targeting by CRISPR-Cas9. Elife. 2018;7. DOI:10.7554/eLife.32724.
- Cui J, Techakriengkrai N, Nedumpun T, et al. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci Rep. 2020;10(1):1–13. https://www.nature.com/articles/s41598-020-66775-3
- Wu W, Orr-Burks N, Karpilow J, et al. Development of improved vaccine cell lines against rotavirus. Sci Data. 2017;4(1):1–12. https://www.nature.com/articles/sdata201721
- Hoeksema F, Karpilow J, Luitjens A, et al. Enhancing viral vaccine production using engineered knockout vero cell lines – a second look. Vaccine. 2018;36(16):2093–2103.
- Sharon DM, Nesdoly S, Yang HJ, et al. A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms. Sci Rep. 2020;10(1):1–15. https://www.nature.com/articles/s41598-020-68934-y
- Orr-Burks N, Murray J, Wu W, et al. Gene-edited vero cells as rotavirus vaccine substrates. Vaccine X. 2019;3:100045.
- Roointan A, Morowvat MH. Road to the future of systems biotechnology: CRISPR-Cas-mediated metabolic engineering for recombinant protein production.Biotechnol Genet Eng Rev. 2016;32(1–2):74–91.
- Kalemera MD, Capella-Pujol J, Chumbe A, et al. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. J Gen Virol. 2021:102(1). DOI:10.1099/jgv.0.001512.
- Jia YL, Guo X, Lu JT, et al. CRISPR/Cas9-mediated CRISPR /Cas9-mediated gene knockout for DNA methyltransferase Dnmt3a in CHO cells displays enhanced transgenic expression and long-term stability. J Cell Mol Med. 2018;22(9):4106–4116. https://europepmc.org/articles/PMC6111867
- Sergeeva D, Camacho-Zaragoza JM, Lee JS, et al. CRISPR/Cas9 as a Genome Editing Tool For Targeted Gene Integration In CHO cells. Methods Mol Biol. 2019;1961:213–232 doi:https://doi.org/10.1007/978-1-4939-9170-9_13.
- Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52(6):1555–1564. https://pubs.acs.org/doi/full/10.1021/acs.accounts.9b00106
- Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295–304.
- Nunes FA, Furth EE, Wilson JM, et al. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther. 1999;10(15):2515–2526.
- Lau CH, Suh Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res. 2017;6:2153. https://f1000research.com/articles/6-2153
- Naso MF, Tomkowicz B, Perry WL, et al. Adeno-Associated Virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317–334. https://link.springer.com/article/10.1007/s40259-017-0234-5
- Davidsson M, Negrini M, Hauser S, et al. A comparison of AAV-vector production methods for gene therapy and preclinical assessment. Sci Rep. 2020:10(1). DOI:10.1038/s41598-020-78521-w.
- Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med. 2013;19(7):889–891. https://www.nature.com/articles/nm.3230
- Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence. 1994;91:10039–10043. Accessed 18 April 2022 doi:https://doi.org/10.1073/2Fpnas.91.21.10039
- Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proceedings of the National Academy of Sciences. 1996;93:7966–7972. [Accessed18 April 2022] doi:https://doi.org/10.1073/2Fpnas.93.15.7966.
- Xu ZX, Chen JZ, Yue YB, et al. A 16-bp RBE element mediated Rep-dependent site-specific integration in AAVS1 transgenic mice for expression of hFIX. Gene Ther. 2009;16(5):589–595 [Accessed 18 April 2022]. https://www.nature.com/articles/gt20099
- Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation.Nat Biotechnol. 2015;33(2):139–142.
- Kunze C, Börner K, Kienle E, et al. Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia. 2018;66(2):413–427. https://onlinelibrary.wiley.com/doi/full/10.1002/glia.23254
- Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors.Mol Ther. 2004;10(4):616–629.
- Armentano D, Sookdeo CC, Hehir KM, et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. 2008;6:1343–1353 [cited 18 April 2022]. https://www.liebertpub.com/doi/abs/10.1089/hum.1995.6.10-1343
- Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proceedings of the National Academy of Sciences. 1996;93:13565–13570. https://www.pnas.org/content/93/24/13565 [cited 18 April 2022]
- Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production.Mol Ther. 2003;8(5):846–852.
- Shin J, Lee N, Cho S, et al. Targeted genome editing using DNA-Free RNA-guided cas9 ribonucleoprotein for CHO cell engineering. Methods Mol Biol. 2018;1772:151–169. https://link.springer.com/protocol/10.1007/978-1-4939-7795-6_8
- Senturk S, Shirole NH, Nowak DG, et al. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun. 2017;8(1):1–10. https://www.nature.com/articles/ncomms14370
- Banaszynski LA, Chun CL, Maynard-Smith LA, et al. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell. 2006;126(5):995–1004. http://www.cell.com/article/S0092867406010130/fulltext
- Lattanzi A, Meneghini V, Pavani G, et al. Optimization of CRISPR/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements. Mol Ther. 2019;27(1):137–150.
- Keen EC. Phage therapy: concept to cure. Front Microbiol. 2012;3:238.
- Tao P, Zhu J, Mahalingam M, et al. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev. 2019;145:57–72.
- Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.Nat Biotechnol. 2014;32(11):1141–1145.
- Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146–1150. https://www.nature.com/articles/nbt.3043
- Yosef I, Manor M, Kiro R, et al. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A. 2015;112(23):7267–7272. https://www.pnas.org/content/112/23/7267
- Yosef I, Goren MG, Globus R, et al. Extending the host range of bacteriophage particles for DNA transduction. Mol Cell. 2017;66(5):721–728.e3. http://www.cell.com/article/S1097276517303106/fulltext
- Mout R, Ray M, Lee YW, et al. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges. Bioconjug Chem. 2017;28(4):880–884.
- Lino CA, Harper JC, Carney JP, et al.Delivering CRISPR: a review of the challenges and approaches. Drug Delivery. 2018;25(1):1234–1257.
- Pattanayak V, Lin S, Guilinger JP, et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013;31(9):839–843. https://pubmed.ncbi.nlm.nih.gov/23934178/
- Sullivan NT, Allen AG, Atkins AJ, et al. Designing safer CRISPR/Cas9 therapeutics for HIV: defining factors that regulate and technologies used to detect off-target editing. Front Microbiol. 2020;11:1872.
- Bayat H, Omidi M, Rajabibazl M, et al. The CRISPR growth spurt: from bench to clinic on versatile small RNAs. J MicrobiolBiotechnol. 2017;27:207–218 [cited 18 April 2022]. https://pubmed.ncbi.nlm.nih.gov/27840399/
- Fu Y, Sander JD, Reyon D, et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32(3):279–284.
- Singh R, Kuscu C, Quinlan A, et al. Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. Nucleic Acids Res. 2015;43(18):e118–e118. https://pubmed.ncbi.nlm.nih.gov/26032770/
- Philippe N, Legendre M, Doutre G, et al. Pandoraviruses: amoeba viruses with genomes up to 2.5 Mb reaching that of parasitic eukaryotes. Science 1979). 2013;341(6143):281–286. https://www.science.org/doi/abs/10.1126/science.1239181
- Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–495. https://www.nature.com/articles/nature16526
- Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science 1979). 2016;351(6268):84–88 [cited 18 April 2022]. https://www.science.org/doi/abs/10.1126/science.aad5227
- Guo N, Liu J-B, Li W, et al. The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy. J Adv Res. 2021. DOI:10.1016/j.jare.2021.11.018.
- Samulski RJ, Muzyczka N AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. https://doi.org/10.1146/annurev-virology-031413-085355.
- Jiang S, Wang LW, Walsh MJ, et al. CRISPR/Cas9-mediated genome editing in epstein-barr virus-transformed lymphoblastoid B-cell lines. Curr Protoc Mol Biol. 2018;121(1):31.12.1–31.12.23. https://onlinelibrary.wiley.com/doi/full/10.1002/cpmb.51
- Park A, Hong P, Won ST, et al. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev. 2016;3:16057.
- Mansouri M, Ehsaei Z, Taylor V, et al. Baculovirus-based genome editing in primary cells. Plasmid. 2017;90:5–9.